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CRH is a key regulator of neuroendocrine, autonomic, and behavioral response to stress. CRH-
stimulated CRH receptor 1 (CRHR1) activates ERK1/2 depending on intracellular context. In a
previous work, we demonstrated that CRH activates ERK1/2 in limbic areas of the mouse brain
(hippocampus and basolateral amygdala). ERK1/2 is an essential mediator of hippocampal phys-
iological processes including emotional behavior, synaptic plasticity, learning, and memory. To
elucidate the molecular mechanisms by which CRH activates ERK1/2 in hippocampal neurons, we
used themouse hippocampal cell line HT22.We document for the first time that ERK1/2 activation
in response to CRH is biphasic, involving a first cAMP- and B-Raf–dependent early phase and a
second phase that critically depends on CRHR1 internalization and -arrestin2. By means of
mass-spectrometry–based screening, we identified B-Raf–associated proteins that coimmunopre-
cipitate with endogenous B-Raf after CRHR1 activation. Using molecular and pharmacological
tools, the functional impact of selected B-Raf partners in CRH-dependent ERK1/2 activation was
dissected. These results indicate that 14-3-3 proteins, protein kinase A, and Rap1, are essential for
early CRH-induced ERK1/2 activation, whereas dynamin and vimentin are required for the CRHR1
internalization-dependent phase. Both phases of ERK1/2 activation depend on calcium influx and
are affected by calcium/calmodulin-dependent protein kinase II inactivation. Thus, this report
describes the dynamics and biphasic nature of ERK1/2 activation downstreamneuronal CRHR1 and
identifies several new critical components of the CRHR1 signaling machinery that selectively
controls the early and late phases of ERK1/2 activation, thus providing new potential therapeutic
targets for stress-related disorders. (Molecular Endocrinology 27: 491–510, 2013)
The 41-amino acid peptide CRH plays a key role in theregulation of neuroendocrine, autonomic, and behav-
ioral response to stress (1, 2). Hypothalamic CRH medi-
ates basal and stress-induced responses through hypotha-
lamic-pituitary-adrenal axis activation, whereas central
extrahypothalamic CRH modulates a wide range of ad-
aptations, including anxiety-like behaviors (3, 4). Dys-
regulation of the CRH system is implicated in human
stress-related affective disorders, mainly anxiety and de-
pression (2, 5–7).
CRH exerts its actions by activating 2 distinct G
protein-coupled receptors (GPCRs), CRH receptor 1
(CRHR1), and CRH receptor 2 (CRHR2), that display
not only specific expression patterns throughout the brain
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but also different ligand affinities: CRH is a high-affinity
ligand for CRHR1 and binds poorly to CRHR2 for
which other ligands such as urocortin II and III have
higher affinity (8, 9).
A large number of preclinical and clinical studies have
clearly described the involvement of CRHR1 in the onset
andmaintenance of stress-related disorders (6, 10–13). In
this regard, conditional CRHR1-knockout mice have
provided interesting information: although mice lacking
the CRHR1 in all principal neurons of the forebrain show
reduced anxiety-related behavior (11), a recent work that
analyzed behavioral effects of CRHR1 deletions in neu-
rotransmitter-specific neurons shows that the receptor
exerts different functions (anxiogenesis vs anxiolysis) act-
ing on different neuronal populations (14). These novel
results suggest that transitions from physiological to
pathological states may be regulated by a delicate balance
of the CRH/CRHR1 system.
In most systems, activated CRHRs bind the Gs pro-
tein, resulting in adenylyl cyclase (AC) stimulation with
the consequent increase in intracellular cAMP (reviewed
in Ref. 15). However, CRHR1 downstream signaling is
far more complex than previously thought.
In fact, recent reports indicate that CRHR1 is able to
activate different intracellular pathways depending on the
cellular context (12, 16–29). One group of signaling mol-
ecules that can be activated by CRHR1 depending on the
specific cellular circumstances is the family of MAPKs
ERK1/2. Different results in terms of ERK1/2 activation by
CRH have been reported. In particular cellular systems,
CRH increases cAMP intracellular levels but is ineffective in
activating ERK1/2 (20–22). On the other hand, under dif-
ferent cellular circumstances, CRH is able to trigger a
MAPK signal transduction pathway via cAMP (23–26, 29).
In vivo studies demonstrated that MAPKs ERK1/2 are
activated by acute intracerebroventricular administration
of CRH in specific limbic areas such as hippocampus and
basolateral amygdala. These brain structures are func-
tionally involved in environment information processing
and behavioral adaptation to stress (12). However, other
regions with high CRHR1 expression levels such as cor-
tex, hypothalamic nuclei, and the central nucleus of the
amygdala did not show CRH-mediated ERK1/2 activa-
tion (12). The fact that CRH injection triggers such a
specific activation pattern suggests that a molecular
and functional link between CRHR1 and downstream
MAPKs may be restricted to these brain structures (19).
ERK1/2 is widely distributed through the central ner-
vous system (CNS) and is highly expressed in limbic brain
areas such as the hippocampus, prefrontal cortex, and
basolateral amygdala (30, 31) where it acts as a central
regulator of molecular processes that mediate synaptic
plasticity, learning and memory processes, and emotional
behavior (32–34). In addition, several studies in rodents
indicate that stress can change levels of activated ERK1/2
(35, 36), and pharmacological manipulations of the
ERK1/2 pathway affect different parameters in stress-
coping behavior and anxiety tests (37–39). Because a
number of CNS disorders in humans are closely related to
the ERK1/2 activation cascade, attention remains focused
on the underlying actions of these molecules (33).
Given that the signal transduction pathways leading to
ERK1/2 activation by CRH depend on cellular context
and that in hippocampal neurons the mechanisms in-
volved are not known,we carried out amolecular analysis
of CRHR1 signaling pathways in HT22 cells, a mouse
hippocampal cell line. Our results reported in this work
demonstrated that these cells are a valuable tool to un-
derstand molecular aspects of CRH signaling, because
this in vitro model proved to be useful to perform molec-
ular and cellular experiments that would be more com-
plex, difficult, and sometimes even unfeasible, in vivo.
Although several studies using non-neuronal cellular
models demonstrated ERK1/2 activation by CRHR1, the
involvement of at least 2 distinct activation mechanisms
(one cAMP-dependent and the other one CRHR1 inter-
nalization-dependent) involving different signaling path-
ways has not been reported to date and may be specific to
the HT22 cellular environment. Several studies using this
immortalized mouse hippocampal cell line consider this
as a suitable model of hippocampal neurons (40–48).
Thus, this is the first report of molecular components and
mechanisms involved in ERK1/2 activation by CRH me-
diated through CRHR1 in a cell model that embrace a
hippocampal cellular context. We identified critical com-
ponents of the CRHR1 signaling machinery that selec-
tively controls the early and late phases of ERK1/2 acti-
vation. These findings may have important implications
for our understanding of the functional connections of the
main signaling pathways controlling CRH actions.
Materials and Methods
Cell culture and generation of cell lines stably
expressing CRHR1
HT22 mouse hippocampal cells were cultured as described
(49). The lack of bona fide commercial antibodies that recognize
CRHR1 with specificity and sensitivity (14) prompted us to use
a c-Myc-CRHR1 construct to generate stable HT22-CRHR1
clones. The use of a mouse monoclonal anti–c-Myc-antibody
allowed us to perform the immunocytochemical (see Figure 2)
and the flow cytometry experiments (see Figure 7B and Supple-
mental Figure 2, published on The Endocrine Society’s Journals
Online web site at http://mend.endojournals.org) shown in this
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work. The mouse CRHR1 expression vector pcDNA3-c-Myc-
mCRHR1 (14) was kindly provided by Dr Jan Deussing (Max
Planck Institute of Psychiatry, Munich, Germany). pcDNA3-c-
Myc-mCRHR1 was used to transfect HT22 cells using Lipo-
fectamine reagent (Life Technologies, Grand Island, New York)
according to themanufacturer’s instructions. For the generation
of cell lines stably expressing CRHR1 (HT22-CRHR1), trans-
fected cells were grown in DMEM (Life Technologies) in the
presence of G418 (800 g/ml; Life Technologies) to select for
transfected cells. G418 surviving clones were subcultured and
maintained inDMEMsupplementedwith 5% (vol/vol) fetal calf
serum (FCS), 4mM L-glutamine (Sigma, St Louis, Missouri), 10
mM HEPES (Sigma), 2.2 mg/ml NaHCO3, 100 U/ml penicillin
(Life Technologies), 100 mg/ml streptomycin (Life Technolo-
gies), and 200 g/ml G418 (Life Technologies) at 37°C in a
humidified 5%CO2 incubator. CRHR1 expression levels in the
stably transfected cell lines was assessed byWestern blot using a
mousemonoclonal anti c-Myc-antibody (1:1000 dilution; Santa
Cruz Biotechnology, Santa Cruz, California). Thirteen positive
clones of HT22-CRHR1 were obtained. All the experiments
were performed at least 2 times with 2 individual clones (clones
2 and 3) with different expression levels of c-Myc-CRHR1.
Data from a representative clone (clone 2) are shown. Using
HT22-CRHR1 clones increased sensitivity in the study by en-
suring that experimental conditions were homogeneous (same
CRHR1 levels in all the experiments).
Small interfering RNA transfection
Chemically synthesized, double-stranded small interfering
RNAs (siRNAs) with 21-nucleotide duplex RNA and 2-nucleotide
3-dTdToverhangswereobtained fromInvitrogen indeprotectedand
desalted form. The siRNA sequences targeting mouse -arrestin1,
-arrestin2, and B-Raf were 5-AAAGCCUUCUGUGCU-
GAGAAC-3 (positions 732–752), 5-AAGGACCGGAAAGU-
GUUCGUG-3 (positions 226–246), and 5-AAGUGGCAUGGU-
GAUGUGGCA-3 (positions 1702–1722), respectively. For vimentin
silencing, siRNA was from a commercial source (Santa Cruz sc-
29523). A nonsilencing RNA duplex (5-CUUACGCUGAGUAC-
UUCGATT-3) was used as a control. For siRNA experiments,
HT22-CRHR1cells (40%confluence)on100-mmdisheswere trans-
fected with 100 nM siRNA inOpti-MEM (Life Technologies), using
24 l of Lipofectamine 2000 Reagent (Life Technologies), according
to themanufacturer’s instructions, and 24 hours later, cells were split
into either 40-mmor6-well dishes and the experiments performed72
hours after transfection.
Transient DNA transfections and plasmids
The expression vectors dynamin-K44A, -arrestin (319–
418) (kindly provided by Dr J. Benovic, Department of Bio-
chemistry andMolecular Biology, Thomas Jefferson University,
Philadelphia, Pennsylvania), Rap1A-17N and Ras-17N (kindly
provided by Dr O. Coso, Laboratorio de Fisiología y Biología
Molecular, Universidad de Buenos Aires, Buenos Aires, Argen-
tina) were used. HT22-CRHR1 cells grown in 100-mm dishes
(50% confluent) were transiently transfected with plasmids (6
g) using 36 l of Lipofectamine reagent combined with 24 l
of PLUS Reagent (Life Technologies) following the manufactur-
er’s instructions, and 24 hours later, cells were split into either
40-mm or 6-well dishes and experiments performed 48 hours
after transfection. The plasmid expressing the dominant-nega-
tive (DN)–14-3-3 (R56A, R60A), (kindly provided by Dr A. S.
Shaw, Department of Pathology and Immunology, Washington
University School of Medicine, St Louis, Missouri)A. S. was
used at the amounts indicated (see Figure 6).
Ligand stimulation, drugs, and
pharmacological inhibitors
HT22 and HT22-CRHR1 cells on 6-well or 40-mm plates
were starved for 18 hours in Opti-MEM before stimulation or
drug pretreatments. Cells were stimulated with human/rat CRH
(H-2435; Bachem, Torrance, California) or with platelet-de-
rived growth factor (PDGF) (01-305; Millipore, Billerica, Mas-
sachusetts) at the concentrations and time points indicated in
the figures. After incubations, cells were washed with ice-cold
PBS and maintained in ice. When CRHR1 antagonist DMP696,
calcium chelator 1,2-Bis(2-aminophenoxy)ethane-N,N,N,N-tet-
raacetic acid tetrakis(acetoxymethyl ester) (BAPTA-AM) (5 M)
(B6769; Life Technologies), extracellular EGTA (2 mM) or phar-
macological inhibitors were used, cells were pretreated with the
drugs (or vehicle) 30 minutes before stimulation. CRHR1-specific
antagonist DMP696 (5 M) was a generous gift from Dr Hausch
(Max Planck Institute of Psychiatry,Munich, Germany). Receptor
internalization was inhibited by pretreatment with phenylarsine
oxide (2.5 M; Sigma) or monodansylcadaverine (100 M;
Sigma). Adenylate cyclase, protein kinase A (PKA), calcium/cal-
modulin-dependent protein kinase (CaMKII), phospholipase C
(PLC), and MAPK kinase (MEK)1/2 were inhibited with 2,5-
dideoxyadenosine (2,5–ddA) (50 M; Calbiochem, La Jolla,
California), H89 (10 M; Calbiochem), KN-62 (10 M; Calbio-
chem), U-73122 (5 M; Sigma), and UO126 (10 M; Calbio-
chem), respectively. All pretreatments and stimulations were car-
ried out at 37°C in a humidified incubator at 5% CO2.
Preparation of cellular extracts
and immunoblotting
After treatments, cells were washed with ice-cold PBS and
lysed directly in Laemmli sample buffer. Whole-cell lysates were
sonicated, heated to 95°C for 5 minutes, and cooled on ice.
Samples were resolved by SDS-PAGE and transferred onto ni-
trocellulose membranes (Millipore) for immunoblotting. Mem-
branes were blocked in TBS-Tween 20 (0.05%) containing 5%
milk at room temperature for 1 hour under shaking and probed
overnight at 4°C with the primary antibodies listed below, dis-
solved in the same blocking solution unless it is explicitly de-
fined. Membranes were incubated with the corresponding sec-
ondary antibodies, and antibody binding was detected by
enhanced chemiluminescence (ECL; Pierce, Rockford, Illinois)
using an LAS-1000 imaging system (Fujifilm, Tokyo, Japan).
The following antibodies were used: anti–c-Myc, anti–phos-
pho-ERK1/2 (pERK1/2), anti–pan-14-3-3, antivimentin, anti–to-
tal-B-Raf (Santa Cruz Biotechnology); anti–phospho-B-Raf Ser44,
anti–total-ERK1/2, anti-phospho-CaMKIIThr286 (Cell Signaling,
Danvers, Massachusetts); anti–-arrestin (BD Transduction Lab-
oratories, Lexington,Kentucky). Tonormalize the phosphorylated
isoforms of ERK1/2 and B-Raf to their total expression level, after
stripping, membranes were incubated with total ERK1/2 or with
total B-Raf antibodies. Immunoreactive signals were quantified by
densitometry using ImageJ software (http://rsbweb.nih.gov/ij/, Na-
tional Institutes of Health).
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Immunoprecipitation assays
HT22-CRHR1 cells were grown to 70% confluence and se-
rum starved with Opti-MEM (Gibco) 18 hours before being
stimulated with 100 nM CRH. After treatments, cells were
washed with ice-cold PBS and lysed for 2 h at 4°Cwith modified
RIPA buffer (50 mM Tris [pH 7.4], 100 mM NaCl; 1 M
EDTA; 1% Nonidet P-40) containing a cocktail of protease
inhibitors (Roche Molecular Biomedicals, Indianapolis, Indi-
ana). To maximize the recovery of the B-Raf–interacting pro-
teins, three 100-mm dishes were used for each condition. Im-
munoprecipitation assays were performed at 4°C overnight
with rabbit anti–B-Raf antibodies raised against an epitope cor-
responding to amino acids 12–156 mapping at the N terminus
of B-Raf (1 g) (sc-9002; Santa Cruz Biotechnology). Immuno-
precipitates were collected using protein A/G plus agarose
(Santa Cruz Biotechnology). A preclearing step with a commer-
cial polyclonal nonimmune rabbit antibody (sc-2345; Santa
Cruz Biotechnology) and protein A/G plus agarose (Santa Cruz
Biotechnology) was included before performing B-Raf immuno-
precipitation to prevent nonspecific protein binding to the anti–
B-Raf rabbit polyclonal antibody. Immunoprecipitates were
washed once with modified RIPA buffer and once with cold PBS
and resuspended in Laemmli sample buffer. After heating at
95°C for 5minutes, the samples were centrifuged briefly and the
supernatants were run by SDS-PAGE. After electrophoresis,
proteins were stained by Coomassie Brilliant Blue following the
manufacturer’s protocol (Bio-Rad, Hercules, California) and
scanned with the densitometer GS-800 using the PDQuest soft-
ware (Bio-Rad).
Proteomic analysis by liquid chromatography-
electrospray ionization-tandem mass spectrometry
Gel lanes were cut in 23 equal slices and in-gel tryptic diges-
tion was performed as previously described (49). The extracted
peptides were lyophilized and dissolved in 10 l 0.1% formic
acid aqueous solution (Merck, Darmstadt, Germany). Five mi-
croliters were then loaded onto an in-house packed fused silica
nano RP-C18 column (0.075 mm  20 cm) using 5 m inner
diameter packing material (Maisch, Monheim, Germany). The
nano columnwas washed with 0.1% formic acid for 10minutes
and elutedwith a gradient of 95%acetonitrile/0.1% formic acid
from 2% to 10% in 2 minutes, from 10% to 45% in 45 minutes
at a flow rate of 200 nl/min using a nano LC-2D system (Eksi-
gent, Dublin, California) coupled online to an LTQ-Orbitrap
mass spectrometer equipped with a nano spray source (Thermo
Fisher Scientific, Bremen, Germany). The mass spectrometer
was operated in the positive-ion mode, with ion spray voltage of
2 kV, applying a data-dependent automatic scan switch between
mass spectrometry (MS) and MS/MS acquisition. Full scans
were recorded in the Orbitrap mass analyzer at a mass range of
mass to charge ratio of 380–1600 at resolution of 60,000 (mass
to charge ratio of 400) in profile mode. The MS/MS analysis of
the 3most intense peptide ions for each scan was recorded in the
LTQ mass analyzer in centroid mode.
Database searching
The identification of the proteins was achieved by searching
against SwissProt version 15.3 database (uniprot29.05.09),
Mus musculus as taxonomy specie, trypsin as enzyme, and al-
lowing one missed cleavage site. The methionine oxidation and
cysteine carboxyamidomethylation were set as dynamic and
static modifications, respectively. The mass accuracies of the
precursor and the fragment ions were set 20 ppm and 0.7 Da,
respectively. For the peptide identification, the MS/MS spectra
were searched with the support of Mascot version 2.2 (50). The
results with a significance level over 95% were accepted. The
protein identifications were considered confident when at least
2 peptides were contained. The proteins reported in this work
were identified in 2 independent experimental replicates.
Immunofluorescence and confocal microscopy
Cells were seeded on glass coverslips and grown until 50%
confluency. After treatments, cells were washed with ice-cold
PBS and fixed with 4% paraformaldehyde in PBS. Next, cells
were permeabilized with 0.01% Triton X-100/PBS. After a
5-minute wash with PBS, nonspecific binding was reduced by
incubating coverslips with 1% FCS in PBS for 1 hour. Primary
antibodies were diluted 1:200 and incubated overnight at 4°C.
After washing with PBS, cells were incubated with a 1:200 di-
lution of Alexa Fluor 647- or 488-conjugated secondary anti-
bodies (Life Technologies) for 45 minutes at room temperature.
When double staining was carried out, both primary and sec-
ondary antibodies were incubated together. Controls without
primary antibody were performed for each experiment. Cover-
slips were washed with PBS andmounted in Vectashield mount-
ing media with or without propidium iodide (Vector Laborato-
ries, Inc, Burlingame, California) on microscope slides. The
slides were examined with an oil immersion objective (60)
using an FV300 BX61 laser-scanning confocal fluorescence mi-
croscope (Olympus, Center Valley, Pennsylvania) using the ap-
propriate lasers and filters and a confocal slice thickness of 0.45
m. Images were acquired with the Fluoview analyzer program.
For each treatment, between 15 and 20 individual cells were
randomly selected and examined.No fluorescencewas observed
in cells treated with secondary Alexa-Fluor antibodies only. All
images were acquired with the same confocal settings to ensure
uniformity detection for each cell, including pinhole size, detec-
tor gain, offset, and laser power.
Flow cytometry assays
For surface staining, HT22-CRHR1 cells on 100-mm plates
were starved for 18 hours in Opti-MEM before stimulation or
drug pretreatments. Cells were stimulated with 100 nM CRH
for 30 minutes. When pharmacological inhibitors were used,
cells were pretreated with the drugs (or vehicle) 30 minutes
before stimulation. After incubations, cells were washed and
harvested in ice-cold PBS, and 3.0 105 HT22-CRHR1 cells of
each treatment were incubated with 1% FCS in ice-cold PBS for
1 hour in ice water to reduce nonspecific binding. Subsequently,
cells were incubated with 2 g anti-c-Myc for 4 hours in ice
water. After washing with PBS, cells were stained with a 1:100
dilution of antimouse Alexa Fluor 488-conjugated secondary
antibody (Life Technologies) for 1 hour in ice water. Controls
staining parental HT22 cells were performed for each experi-
ment. Flow cytometry data were acquired on a FACSAriaII (Becton
Dickinson,SanJose,California).DatawereanalyzedusingtheFlowJo
software (Tree Star Inc).
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cAMP determination
HT22-CRHR1 cells were grown to 80% confluence in 12- or
24-well plates and serum starved with Opti-MEM for 18 hours.
For concentration-response experiments, cells were incubated
for 5 minutes with 500 M 3-isobutyl-1-methylxanthine and
exposed to CRH at different concentrations for 10 minutes. To
determine EC50 of CRH-induced cAMP production, data were
adjusted with a 3-parameter concentration-response curve with
GraphPad Prism software. Where indicated, cells were pre-
treated for 30minutes with the selective AC inhibitor 2,5-ddA.
Then, cells were subjected to ethanol extraction followed by 15
minutes centrifugation at 3000g. Supernatants were dried and
resuspended in 50mMTris-HCl buffer (pH 7.4). cAMP content
was determined by means of competition with [3H]cAMP for
PKA as described previously (51) and expressed as the percent-
age of stimulation relative to maximal response. The standard
curve was performed using 8 cAMP amounts ranging from 0.1
to 90 pmol. Duplicate samples in at least 3 independent exper-
iments were analyzed.
Calcium imaging
All experiments were performed at room temperature
(20°C–24°C). Cells in 40-mm petri dishes were loaded for 30
minutes in darkness with Fluo-4 AM 6 M (Life Technologies)
and Pluronic F-127 0.14% (Life Technologies) in a Ca2 buffer
(125 mM NaCl, 5 mM KCl, 0.4 mM CaCl2, 1 mM MgSO4, 5
mM NaHCO3, 1 mM Na2HPO4, 10 mM glucose, 20 mM
HEPES [pH 7.4]) and then placed on the stage of a fluorescence
BX-FLA Olympus microscope. Cells were illuminated with a
USH-I 02DH mercury lamp (USHIO) and imaged using a 40
water immersion objective and a cooled CCD Quantix camera
(Photometrix). A filter block containing a 460- to 490-nm ex-
citation filter (band pass), a 505-nm dichroic mirror, and a
515-nm barrier filter (high pass) was used. Exposure times
ranged from 100 to 300 milliseconds, and frames were taken
every 0.4 seconds. Images were acquired with the Axon Imaging
Workbench version 2.1 program and analyzed with Image J
version 1.29v (National Institutes of Health, Bethesda, Mary-
land). Calcium imaging data are presented as F/Fo, where Fo is
the resting fluorescence (before stimulation) and F is the peak
change in fluorescence from resting levels. For quantification,
fluorescence was measured in 4 cells per visual field and at least
3 fields randomly selected in each experiment. Data are pre-
sented as the average  SEM from 3 independent experiments.
Statistics
Each experimentwas performed at least 3 independent times.
The results are presented as the mean  SEM of each measure-
ment. Data were tested for homogeneity, and comparisons be-
tween treatment means were performed using 1-way ANOVA
(GraphPad Prism version 5 for Windows; GraphPad Software,
San Diego California) followed by post hoc Scheffé’s test when
more than 2means were compared (StatView, SAS Institute Inc,
Cary, North Carolina). Statistically significant differences are
indicated.
Results
CRHR1 induces biphasic ERK1/2 activation in a
CRH-stimulated hippocampal cell line
Given our previous findings that established a specific
pattern of ERK1/2 activation in vivo by CRH in the
mouse brain, involving limbic areas such as hippocampus
and amygdala (12), we decided to carry out a molecular
analysis of the signaling components and mechanisms in-
volved. We first analyzed the effects of CRH in terms of
ERK1/2 activation in mouse hippocampal neuronal
HT22 cells. In these cells, unlike CRHR2, CRHR1
mRNA is detected after 18 hours of serum starving (data
not shown). As shown in Figure 1A, CRH induces a bi-
phasic ERK1/2 activation, with a first peak as early as
3–6 6 minutes after stimulation with 100 nM CRH, fol-
lowed by a decline to about basal levels at minute 12.
Remarkably, a second phase of ERK1/2 phosphorylation
was observed at minute 20 (30% of maximal response)
and showed sustained ERK1/2 phosphorylation levels for
at least 60 minutes (Figure 1A). Stable overexpression of
an N-terminal Myc-tagged murine CRHR1 in HT22 cells
(HT22-CRHR1) augments the overall ERK1/2 activation
2-fold at early time points and up to 3-fold in the second
phase (Figure 1B). However, the overall pattern of
ERK1/2 activation is identical for both endogenous and
exogenous receptor expression. In addition, control ki-
netics of ERK1/2 activation performed with vehicle
showed that pERK1/2 levels in the absence of CRH do
not change during the time course of the experiment (Sup-
plemental Figure 1A).
To further validate the role of CRHR1 in mediating
ERK1/2 activation in both parental and HT22-CRHR1
cells, we examined the time course of CRH-induced
pERK1/2 in the presence or absence of DMP696, a
well-defined selective CRHR1 antagonist. As shown in
Figure 1, C and D, 5 M DMP696 pretreatment abol-
ished ERK1/2 activation in both the early phase (3–6
minutes) and the late phase (20–60 minutes), indicating
that CRH-induced ERK1/2 activation is mediated by
CRHR1. In this line, the concentration-response curves,
in which pERK1/2 levels were saturated at high concen-
trations of hormone, also demonstrate a receptor-medi-
ated effect of CRH on ERK1/2 phosphorylation for both
phases of CRH response (Figure 1E).
Subcellular distribution of activated ERK1/2 and
CRHR1 in CRH-stimulated cells
Using indirect immunofluorescence confocal micros-
copy, we examined the spatiotemporal distribution of
pERK1/2 and CRHR1 in HT22-CRHR1 cells after CRH
stimulation (Figure 2). Under basal conditions, a very low
immunoreactive signal of pERK1/2 (pERK1/2 immuno-
reactivity) was homogeneously distributed throughout
the cell. As expected, most of the Myc-tag immunoreac-
tivity corresponding to CRHR1 was detected in the
plasma membrane. However, appreciable CRHR1 signal
was also found intracellularly, likewise it was previously
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observed in cortical neurons trans-
fected with tagged forms of CRHR1
(52). Treatment of the cells with 100
nM CRH promoted CRHR1 internal-
ization (Figure 2 and Supplemental
Figure 2), and a perinuclear accumula-
tion was rapidly observed over time
(Figure 2). After agonist stimulation,
pERK1/2 immunoreactivity increased
with a comparable kinetic to that de-
tected by Western blot (Figures 1, A
and B and 2). At the early time points
of CRH exposure, a small amount of
pERK1/2 immunoreactivity concen-
trated in the cell surface and colocal-
ized with CRHR1 (Figure 2, 3 min-
utes). Noteworthy, most of CRH-
activated ERK1/2 was evidenced as
discrete granular accumulations that
were persistently retained in the cyto-
plasm and cell surface without signifi-
cant translocation into the nucleus.
This pERK1/2 distribution was clearly
different from thepredominantnuclear lo-
cation observed in HT22-CRHR1 cells
stimulated for 5 minutes with PDGF,
another ERK1/2-activating stimulus
(Figure 3). These results indicate that a
specific intracellular pERK1/2 distri-
bution pattern is generated in response
to CRH in HT22-CRHR1 cells.
cAMP on CRH-induced ERK1/2
activation: critical role of B-Raf
Based on previous studies demon-
strating that CRHR1 activation by
CRH triggers ERK1/2 activation down-
stream of cAMP (23–26, 29), we decided
to determinewhether in theHT22 cellular
context, CRH-induced ERK1/2 phos-
phorylation is a consequence of an in-
crease in cAMP levels. To that end, we
first examined the role of AC in
ERK1/2 activation in terms of CRH
signaling. Pretreatment of HT22-
CRHR1 cells with the AC inhibitor
2,5-ddA significantly reduced CRH
ability to activate ERK1/2 at the early
phase (40%), showing no effect on
late time points (Figure 4A). As ex-
pected, themaximum cAMP activation
induced by CRH (after 3 minutes of
Figure 1. Time- and concentration-dependent ERK1/2 activation via CRHR1 in HT22 cells. A
and B, pERK1/2 and total ERK1/2 were determined by Western blot in HT22 (A) or HT22-
CRHR1 (B) cells stimulated with 100 nM CRH for the indicated time points. C and D, pERK1/2
and total ERK1/2 were determined by Western blot in HT22 (C) or HT22-CRHR1 (D) cells
stimulated with 100 nM CRH for the indicated time points after preincubation in the presence
of vehicle or the CRHR1 antagonist DMP696 (5 M). A–D, Signals were quantified by
densitometry as described in Materials and Methods, and each value of pERK1/2 was
normalized to total ERK1/2. Results are expressed as the percentage of maximum pERK1/2
obtained at 3 minutes of stimulation in the absence of antagonist  SEM from 3 independent
experiments. Bottom panels show Western blots of pERK1/2 and total ERK1/2 from a
representative experiment. * P  .05; ** P  .01 with respect to vehicle plus CRH treatment
at the same time point. Statistical analysis was performed using a 1-way ANOVA. E, HT22-
CRHR1 cells were stimulated with CRH at the indicated concentrations for 3 minutes (left
panel) or 40 minutes (right panel). pERK1/2 and total ERK1/2 were determined by Western
blot. Signals were quantified by densitometry as described in Materials and Methods, and
each value of pERK1/2 was normalized to total ERK1/2. Results are expressed as the
percentage of maximal pERK1/2 response obtained at 3 minutes (left panel) or 40 minutes
(right panel)  SEM from 3 independent experiments. To determine EC50 for CRH-induced
ERK1/2 phosphorylation, data were adjusted with a 3-parameter dose-response curve with
GraphPad Prism software. EC50 at 3 minutes was 6.02
11 M (95% confidence interval of
EC50 at 3 minutes, 2.03
11 M to 1.7910 M). EC50 at 40 minutes was 7.16
10 M (95%
confidence interval of EC50 at 40 minutes, 2.31
10 M to 2.229 M).
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100 nM CRH) is blocked in cells pretreated with 50 M
2,5ddA (Figure 4B). Interestingly, the EC50 of early-
phase CRH-induced pERK (0.1 nM, Figure 1E, left
panel) is in the same range of the EC50 of CRH-induced
cAMP (0.5 nM, data not shown) in HT22-CRHR1
cells. These results demonstrate that AC and its product,
cAMP, are determining factors for the initial peak in-
crease in CRH-induced ERK1/2 activation.
In cells in which cAMP stimulates ERK activity, B-Raf
constitutes the main activator of the cascade Raf/MEK/
ERK (53). B-Raf is the MAPKKK (MAP kinase kinase
kinase) predominantly expressed in the nervous system
and is highly expressed in HT22 hippocampal cells, as we
previously demonstrated (49). Therefore, we decided to
investigate the role of this MAPKKK in ERK1/2 activa-
tion by CRH. We analyzed the time course of CRH-in-
duced pERK1/2 after depleting cellular levels of B-Raf by
transfecting HT22-CRHR1 cells with a siRNA specifi-
cally directed against this protein. Silencing 85% of
B-Raf expression (Figure 4E) led to a significant decrease
of ERK1/2 activation (50%) on the early phase but had
no effect on the late phase, indicating that B-Raf is in-
volved in early CRH-induced ERK1/2 activation (Figure
4C). It is worth mentioning that, in contrast to the effects
observed using CRH, PDGF-stimulated ERK1/2 activa-
tion in the same cells was not affected by B-Raf silencing
(Figure 4D).
B-Raf Ser446 phosphorylation is essential for its
MAPKKK activity (54, 55). We examined by Western
blot the phosphorylation status of B-Raf Ser446 (pB-Raf)
after CRH stimulation. Interestingly, this B-Raf modifi-
cation was transient in HT22-CRHR1 cells (Figure 4F).
pB-Raf was detected after 1 minute of CRH exposure,
preceding in time the peak of early-phase CRH-induced
pERK1/2 (3 minutes) and rapidly returned to basal levels
after 3–6 minutes.
Taken together, these results suggest that active B-Raf
kinase is required to elicit the early phase of pERK1/2.
Moreover, there is a critical and specific role of B-Raf in
mediating early ERK1/2 activation by CRH in HT22-
CRHR1 cells.
Identification of B-Raf partners showing a role in
CRH signaling
In a recent work, we described the B-Raf interactome
in HT22 cells under nonstimulating conditions (49).
Given the critical role of this MAPKKK in mediating
ERK1/2 activation by CRH in HT22-CRHR1 cells and
that proteins do not act in isolation to fulfill their diverse
functions, we performed B-Raf immunoprecipitation fol-
lowed by MS in CRH-treated cells with the aim of iden-
tifying B-Raf partners with a potential role in CRH
signaling in terms of ERK1/2 activation (Figure 5). Coim-
munoprecipitated proteins with endogenous B-Raf ob-
tained from lysates of CRH-treated HT22-CRHR1 cells
were resolved by SDS-PAGE and subjected to in-gel pro-
teolytic digestion. The resulting proteolytic peptides were
analyzed by liquid chromatography-electrospray ioniza-
Figure 2. pERK1/2 and c-Myc–CRHR1 subcellular distribution induced by CRH in HT22-CRHR1 cells. pERK1/2 and c-Myc–CRHR1 distribution was
monitored over different time points after 100 nM CRH stimulation by indirect double immunofluorescence using specific antibodies against
pERK1/2 (green) and c-Myc (red) as described in Materials and Methods. Cell nuclei were stained with the DNA-specific dye propidium iodide (PI)
(blue). pERK1/2 and CRHR1 colocalization appears as yellow in the merged images. Scale bar, 20 M.
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tion-tandem MS, and the identification of sequences was
performed by the use of Mascot algorithm. At first, those
proteins with a potential role in cellular signaling were
selected by extracting and mining biological relationships
from biomedical literature. Finally, a list of B-Raf part-
ners whose function in CRH-induced ERK1/2 activation
has been confirmed in this work was created (Table 1).
The 14-3-3 proteins interact with many different cel-
lular phosphoproteins and play a central role in the acti-
vation process of Raf kinases (56). We identified the 7
mammalian isoforms of these proteins in association with
B-Raf (Table 1). Homodimeric and heterodimeric forms
of 14-3-3 associate with B-Raf (57). To evaluate the bio-
logical function of 14-3-3 in the B-Raf–dependent phase
of CRH-induced ERK1/2 activation, we used the double
arginine mutant forms (R56A and R60A) of 14-3-3
(DN–14-3-3). Because DN–14-3-3 forms generate inac-
tive heterodimers with endogenous 14-3-3 monomers
(58) and taking into account that 14-3-3 proteins are
highly abundant in CNS, different amounts of DN–14-
3-3 were transfected in HT22-CRHR1 cells. Although
0.2 g of DN–14-3-3 did not show changes in pERK1/2
signal in response to 3 minutes of stimulation with 100
nM CRH, 0.6 g of plasmid substantially reduced
ERK1/2 phosphorylation. Furthermore, the higher the
amount of transfected DN–14-3-3, the higher the inhi-
bition of CRH-induced ERK1/2 activation (Figure 6A).
Therefore, we conclude that 14-3-3 proteins, previously
identified as B-Raf partners (57), are essential at early
time points of ERK1/2 activation induced by CRH in
HT22-CRHR1 cells.
Previous work in corticotrophs demonstrated that a
rapid CRH/CRHR1-triggered ERK1/2 activation takes
place downstream of PKA and B-Raf (24). In addition,
B-Raf activation via PKAwas also previously described in
PC12 cells used as aneuronal model (59). In this work, we
identified the catalytic subunit of the PKA in a complex
with B-Raf (Table 1). To evaluate the dependence of
ERK1/2 activation on PKA activity, we examined the time
course of CRH-induced pERK1/2 in the presence or ab-
sence of H89, a selective PKA inhibitor. In line with the
observed effects of inhibiting AC and B-Raf, 10 MH89
Figure 3. pERK1/2 subcellular distribution induced by CRH and PDGF in HT22-CRHR1 cells. HT22-CRHR1 cells were stimulated with 100 nM CRH
for 3 minutes or 10 ng/ml PDGF for 5 minutes. pERK1/2 distribution was monitored by indirect immunofluorescence using specific antibodies
(green) as described in Materials and Methods. Cell nuclei were stained with the DNA-specific dye propidium iodide (PI) (blue). Colocalization
appears as cyan in the merged images. Scale bar, 20 M.
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pretreatment reduced most of the ERK1/2 activation on
the early phase (60%) but had no significant effects on
the late time points, indicating that PKA is the principal
target of the second-messenger cAMP involved in early
CRH-induced ERK1/2 activation (Figure 6B).
Several studies have demonstrated that the small G pro-
tein Rap1, like Ras, activates theMEK/ERK signaling path-
way through activation of B-Raf (60). A Rap1/B-Raf com-
plex as a consequence of PKAactivationhas beenpreviously
identified in PC12 cells (59). In CRH-treated HT22-
CRHR1 cells, we found B-Raf in association with Rap1
(Table 1). To investigate the role of these 2members of small
G proteins, we examined the effect of a DNmutant of Rap1
(Rap1A-17N) or a DN form of Ras (Ras-17N) on CRH-
induced ERK1/2 activation inHT22-CRHR1 cells. ERK1/2
phosphorylation after CRH stimulation was significantly
inhibited (50%) either by Rap1A-17N or by Ras-17N
only in the early phase (Figure 6C). These data indicate that
Rap1 and Ras are also involved in the activation of ERK1/2
induced by CRH at early time points.
Figure 4. Role of AC and specific requirement of B-Raf for early CRH-induced ERK1/2. A and B, HT22-CRHR1 cells were stimulated with 100 nM CRH
for the indicated time points after preincubation in the presence of vehicle or the AC inhibitor 2,5-ddA (50 M) for 30 minutes. pERK1/2 and total
ERK1/2 (A) were determined by Western blot; signals were quantified by densitometry as described in Materials and Methods, and each value of pERK1/2
was normalized to total ERK1/2. Results are expressed as the percentage of maximum pERK1/2 obtained at 3 minutes of stimulation in control
conditions SEM from 3 independent experiments. Bottom panels show Western blots of pERK1/2 and total ERK1/2 from a representative experiment. *
P .05; ** P .01 with respect to vehicle plus CRH treatment at the same time point. Statistical analysis was performed using a one-way ANOVA.
cAMP levels (B) were determined by means of competition with [3H]cAMP for PKA as described in Materials and Methods. Results are expressed as the
percentage of maximum cAMP levels obtained at 3 minutes of stimulation SEM from 3 independent experiments. ** P .01 compared with the basal
(time 0 minutes) in the presence of vehicle. Statistical analysis was performed using a one-way ANOVA followed by post hoc Scheffé’s test. C and D,
HT22-CRHR1 cells were transfected with 100 nM scramble or 100 nM B-Raf siRNA as described in Materials and Methods. Cells were stimulated with
100 nM CRH (C) or 10 ng/ml PDGF (D) for the indicated time points and pERK1/2 and total ERK1/2 were determined by Western blot. Signals were
quantified by densitometry as described in Materials and Methods, and each value of pERK1/2 was normalized to total ERK1/2. Results are expressed as
the percentage of maximum pERK1/2 obtained at 3 minutes (C) or 5 minutes (D) of stimulation in control conditions SEM from 3 independent
experiments. Bottom panels show Western blots of pERK1/2 and total ERK1/2 from a representative experiment. * P .05; ** P .01 compared with
control treatment (scramble siRNA) at the same time point. Statistical analysis was performed using a one-way ANOVA. E, Western blot of B-Raf and
glyceraldehyde 3-phosphate dehydrogenase as a loading control from a representative siRNA experiment. F, pB-Raf (top panel), pERK1/2 (middle panel),
and total B-Raf (bottom panel) in HT22-CRHR1 cells stimulated with 100 nM CRH at different time points were determined by Western blot. A
representative Western blot from 3 independent experiments is shown.
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MEK1/2 are dual-specificity kinases that phosphory-
late the tyrosine and threonine residues on ERK1/2 re-
quired for their activation. MEK1/B-Raf interaction was
previously described (61). BecauseMEK1was detected in
B-Raf immunoprecipitates from CRH-treated cells, we
analyzed the effect of UO126, a selective MEK1/2 inhib-
itor, on CRH-induced ERK1/2 activation. As expected,
no pERK1/2 signal was detected when HT22-CRHR1
cells were pretreated with the MEK1/2 inhibitor (Supple-
mental Figure 1B).
Taken together, these results indicate that B-Raf and
specific identified partners (14-3-3 proteins, PKA, Rap1,
and MEK1/2) are essential players of early time points of
CRH-induced pERK1/2.
CRHR1 internalization and -arrestins are required
for CRH-induced ERK1/2 activation
Clathrin-mediated endocytosis involves recruitment of
clathrin to forming pits and the scission of vesicles from
the plasma membrane induced by the GTPase dynamin.
We identified dynamin as a B-Raf partner in CRH-treated
cells (Table 1). To assess a potential role of dynamin in
CRH-induced pERK1/2, HT22-CRHR1 cells were trans-
fectedwith dynaminDNmutant (dynamin-K44A), an effec-
tive inhibitor of clathrin-mediated endocytosis. In this case,
interestingly,we found that dynamin-K44Atransfection sig-
nificantly reduced ERK1/2 activation of the late phase
(40%) compared with control cells (Figure 7A).
Several studies have demonstrated that, at least in cer-
tain cell types, GPCR internalization is required for acti-
vation of downstream signaling cascades including those
leading to ERK1/2 phosphorylation (18, 62, 63). Given
that dynamin is involved in CRH-induced ERK1/2 acti-
vation of the late phase (Figure 7A) and a link between
CRHR endocytosis and ERK1/2 activation has been de-
scribed in peripheral cell line expression systems (18), we
investigated the relationship between CRHR1 internal-
ization and ERK1/2 activation in our neuronal model
HT22-CRHR1 cells. To that end, we evaluated the effects
of different endocytosis inhibitors on CRH-induced
ERK1/2 activation. Pretreatment of cells with 2.5 M
phenylarsine oxide (PAO), a general endocytosis inhibi-
tor, or with 100	 monodansylcadaverine (MDC), a
specific blocker of clathrin-mediated endocytosis, signif-
icantly reduced CRHR1 internalization after 30 minutes
of agonist stimulation (Figure 7B). Interestingly, impaired
CRHR1 endocytosis was accompanied by a decrease to
nearly basal levels in ERK1/2 activation after 30 minutes
of CRH (Figure 7C).
-arrestins specifically target GPCRs for internaliza-
tion by clathrin-coated vesicles and have also been de-
scribed as mediators of diverse signaling pathways within
the cell, including ERK1/2 activation (63). We investi-
gated the role of -arrestin1 and -arrestin2 in CRH-
induced ERK1/2 activation in HT22-CRHR1 cells. We
first analyzed the effect of the clathrin-binding domain of
-arrestin -arr (319–418), which functions as a DN by
Figure 5. Identification of B-Raf partners with a role in CRH
signaling. A schematic representation of the approach used to identify
B-Raf partners with a role in CRH signaling is depicted (see text). The
list of B-Raf partners whose function in CRH-induced ERK1/2 activation
has been confirmed in this work is shown in Table 1.
Table 1. B-Raf Partners Identified From CRH-Stimulated
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Figure 6. Involvement of B-Raf partners in the early CRH-induced ERK1/2 activation. A, HT22-CRHR1 cells were transfected with increasing
amounts of DN–14-3-3 as indicated. Cells were stimulated with 100 nM CRH for 3 minutes. pERK1/2 (top panel), total ERK1/2 (middle panel),
and total 14-3-3 proteins (endogenous and transfected) were determined by Western blot. Note that c-Myc–DN–14-3-3s have slower gel mobility
compared with endogenous 14-3-3s. B, HT22-CRHR1 cells were pretreated for 30 minutes with 10 M H89 and stimulated with 100 nM CRH for
the indicated time points. Controls were preincubated with vehicle. pERK1/2 and total ERK1/2 were determined by Western blot; signals were
quantified by densitometry as described in Materials and Methods, and each value of pERK1/2 was normalized to total ERK1/2. Results are
expressed as the percentage of maximum pERK1/2 obtained at 3 minutes of stimulation in the absence of inhibitor  SEM from 3 independent
experiments. Bottom panels show Western blots of pERK1/2 and total ERK1/2 from a representative experiment. * P  .05; ** P  .01 compared
with vehicle plus CRH treatment at the same time point. Statistical analysis was performed using a one-way ANOVA. C, HT22-CRHR1 cells were
transfected with 600 ng RapN17A, 600 ng RasN17A, or the empty vector. Cells were stimulated with 100 nM CRH for the indicated time points,
and pERK1/2 and total ERK1/2 were determined by Western blot. Signals were quantified by densitometry as described in Materials and Methods,
and each value of pERK1/2 was normalized to total ERK1/2. Results are expressed as the percentage of maximum pERK1/2 obtained at 3 minutes
of stimulation in control conditions  SEM from 3 independent experiments. Bottom panels show Western blots of pERK1/2 and total ERK1/2
from a representative experiment. * P  .05; ** P  .01 compared with control treatment (empty vector) at the same time point. Statistical
analysis was performed using a one-way ANOVA followed by post hoc Scheffé’s test.
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preventing -arrestin interaction with receptors. -Arr
(319–418) expression significantly decreased pERK1/2
in the late phase of CRH stimulation (50%) (Figure
7D). To evaluate the contribution of each -arrestin iso-
form, we analyzed the time course of CRH-induced
pERK1/2 after depleting cellular levels of -arrestin1 or
-arrestin2 by alternatively transfecting cells with a
siRNA specifically directed against each isoform. Silenc-
Figure 7. CRHR1 internalization and -arrestin2 requirement for CRH-induced ERK1/2 activation. A and D, HT22-CRHR1 cells were transfected
with 600 ng dynamin-K44A (A) or 600 ng -arr (319–418) (D) as described in Materials and Methods. Cells were stimulated with 100 nM CRH for
the indicated time points and pERK1/2 and total ERK1/2 were determined by Western blot. Signals were quantified by densitometry as described in
Materials and Methods, and each value of pERK1/2 was normalized to total ERK1/2. Results are expressed as the percentage of maximum pERK1/2
obtained at 3 minutes of CRH stimulation under control conditions  SEM from 3 independent experiments. Bottom panels show Western blots of
pERK1/2 and total ERK1/2 from a representative experiment. * P  .05; ** P  .01 compared with control treatment (empty vector) at the same
time point. Statistical analysis was performed using a one-way ANOVA. B, HT22-CRHR1 cells were pretreated for 30 minutes with vehicle, PAO
(2.5 M), or MDC (100 M) and stimulated with 100 nM CRH for 30 minutes. Using specific antibodies against c-Myc, tagged-receptor
distribution was monitored by indirect immunofluorescence in fixed and permeabilized HT22-CRHR1 cells (red). c-Myc–CRHR1 internalization was
quantified by flow cytometry, labeling cell surface with c-Myc antibody. HT22 cells were used as control. A representative flow cytometry
experiment is shown. c-Myc–CRHR1 internalization quantifications are expressed as the percentage of maximum receptor on cell surface
(nonstimulated HT22-CRHR1 cells)  SEM from 3 independent experiments. ** P  .01 compared with nonstimulated HT22-CRHR1 cells.
Statistical analysis was performed using a one-way ANOVA followed by post hoc Scheffé’s test. C, HT22-CRHR1 cells were pretreated for 30
minutes with vehicle, PAO (2.5 M), or MDC (100 M) and stimulated with 100 nM CRH for 30 minutes. pERK1/2 and total ERK1/2 were
determined by Western blot. Signals were quantified by densitometry as described in Materials and Methods, and each value of pERK1/2 was
normalized to total ERK1/2. Results are expressed as mean fold increase compared with basal  SEM from 3 independent experiments. Bottom
panels show Western blots of pERK1/2 and total ERK1/2 from a representative experiment. * P  .05 compared with basal. Statistical analysis was
performed using a one-way ANOVA followed by post hoc Scheffé’s test. E, HT22-CRHR1 cells were transfected with 100 nM scramble or 100 nM
-arrestin2 siRNA as described in Materials and Methods. After 18 hours in Opti-MEM, cells were stimulated with 100 nM CRH for different times
and pERK1/2 and total ERK1/2 were determined by Western blot. Signals were quantified by densitometry as described in Materials and Methods,
and each value of pERK1/2 was normalized to total ERK1/2. Results are expressed as the percentage of maximum pERK1/2 obtained at 3 minutes
of stimulation in control conditions  SEM from 3 independent experiments. Bottom panels show Western blots of pERK1/2 and total ERK1/2
from a representative experiment. * P  .05; ** P  .01 compared with control treatment (scramble siRNA) at the same time point. Statistical
analysis was performed using a one-way ANOVA. In the inset is shown a Western blot of -arrestin2 and total ERK1/2 as a loading control from a
representative experiment.
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ing -arrestin1 expression had no significant effect on the
magnitude of the pERK1/2 signal after CRH treatment
(Supplemental Figure 3A). In contrast, silencing -arres-
tin2 expression reducedCRH-induced ERK1/2 activation
on the early phase and led to an almost complete elimi-
nation of pERK1/2 signal from the late phase (75%)
(Figure 7E). As expected, depleting both -arrestin isoforms
simultaneously produced a similar reduction in ERK1/2 acti-
vation to -arrestin2 siRNA-pretreated HT22-CRHR1 cells
(Supplemental Figure 3B). These results demonstrate
that -arrestin2 plays an active and critical role in the
late phase of ERK1/2 activation by CRH.
In an effort to further understand the mechanisms of
CRH signal transduction, we analyzed the time course of
CRH-induced pERK1/2 after depleting cellular levels
of vimentin, a B-Raf partner detected in this work (Table
1) and also previously described as a component of the
B-Raf interactome inHT22 cells (49). Interestingly, trans-
fecting siRNA specifically directed against vimentin led to
an inhibition of ERK1/2 activation in the late phase of
CRH stimulation (55%) (Figure 8A) with a similar pat-
tern to that observed when receptor internalization is al-
tered (compare Figure 7, A, D, and E, with Figure 8A). To
discard a general and nonspecific ERK1/2 inhibition
caused by low cellular levels of vimentin, we analyzed the
B-Raf–independent PDGF-stimulated ERK1/2 activation
pattern in HT22-CRHR1 vimentin-depleted cells. Silenc-
ing vimentin had no effect on ERK1/2 activation by PDGF
(Figure 8B). These results confirm that vimentin plays a
key role in ERK1/2 activation specifically elicited byCRH
in mouse hippocampal HT22-CRHR1 cells.
Taken together, these findings provide evidence that
CRH-induced ERK1/2 activation of the late phase in
HT22-CRHR1 cells requires CRHR1 internalization,
-arrestin2, and vimentin expression.
Calcium in CRH signaling: role of CaMKII
Although CRHR1 mainly couples to the stimulatory
Gs protein, CRH receptors may also stimulate transient
calcium (Ca2) mobilization in certain cell types, depend-
ing on the cellular background, by PLC activation (27,
28). On the other hand, it was also described that CRH
may elicit calcium entry through L-type voltage-depen-
dent calcium channels (24, 64, 65). Because we identified
CaMKII, the major calcium downstream effector, as a
B-Raf partner (Table 1), we investigated the effect of
CRH on intracellular calcium in HT22-CRHR1 cells. As
shown in Figure 9A, CRH elevates intracellular calcium
levels very shortly after stimulation (6 seconds). We
therefore determined whether the cytoplasmic calcium
signal after application of CRH depends on calcium in-
flux from the extracellular environment. To this end, in-
tracellular calciumwas monitored in HT22-CRHR1 cells
stimulated with 100 nMCRH in presence of 2 mM of the
calcium chelator EGTA, to achieve depletion of extracel-
lular calcium. In the presence of EGTA, agonist stimula-
tion failed to induce an increase in intracellular calcium.
Although cell-impermeable EGTA treatment in this assay
may also induce depletion of inositol triphosphate-sensitive in-
tracellular calciumstores, 5MU-73122, apotent inhibitorof
PLC, did not change the measured intracellular calcium trig-
gered by CRH (Figure 9B).
Figure 8. Vimentin is required for the late phase of CRH-induced
ERK1/2. A and B, HT22-CRHR1 cells were transfected with 100 nM
scramble or 100 nM vimentin siRNA as described in Materials and
Methods. Cells were stimulated with 100 nM CRH (A) or 10 ng/ml
PDGF (B) for different times. pERK1/2 and total ERK1/2 were
determined by Western blot. Signals were quantified by densitometry
as described in Materials and Methods, and each value of pERK1/2 was
normalized to total ERK1/2. Results are expressed as the percentage of
maximum pERK1/2 obtained at 3 minutes (A) or 5 minutes (B) of
stimulation in control conditions  SEM from 3 independent
experiments. Bottom panels show Western blots of pERK1/2 and total
ERK1/2 from a representative experiment. * P  .05; ** P  .01
compared with control treatment (scramble siRNA) at the same time
point. Statistical analysis was performed using a one-way ANOVA. The
inset in A shows a Western blot of vimentin and ERK1/2 as a loading
control from a representative experiment.
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Calcium triggers a variety of cellular
responses including MAPK signaling.
In corticotrophs, ERK1/2 activation by
CRH involves L-type voltage-
dependent calcium channel-dependent
and calcium-independent mechanisms
(24). Because calcium channel regula-
tion by cAMP/PKA is a major effector
mechanism for neurotransmitters and
neuromodulators in hippocampal neu-
rons (66), and calcium effects are me-
diated by CaMKII, we decided to ana-
lyze the role of this serine/threonine
kinase identified in this work as a B-
Raf partner (Table 1). To that end, we
examined the time course of pERK1/2
in the presence or absence of KN-62, a
selective CaMKII inhibitor. Interest-
ingly, 10MKN-62 pretreatment sig-
nificantly reduced pERK1/2 levels af-
ter CRH treatment in both phases
(35% of early and 55% of late),
indicating that CaMKII activity is re-
quired for CRH-induced ERK1/2 acti-
vation at early and at late time points
(Figure 9C).
Upon activation, CaMKII phosphor-
ylates a threonine residue (Thr286) in the
autoinhibitory domain of the neighboring
subunitof theCaMKIImultimer(67).This
phosphorylation prevents the autoinhibi-
tory domain from reassociating with the
kinasedomainand is usedas a reporter for
CaMKII activationwithin cells.We exam-
ined byWestern blot the phosphorylation
status of CaMKII Thr286 (pCaMKII) af-
ter CRH stimulation. Phosphorylated
CaMKII (pCaMKII)wasdetectedearlyaf-
ter CRH treatment and throughout the
late phase of ERK1/2 activation. As ex-
pected, pCaMKII levels were severely di-
minished when HT22-CRHR1 cells were
pretreated with KN-62 (Figure 9C). The
CaMKII phosphorylation pattern and the
inhibition of CRH-stimulated ERK1/2 by
KN-62 suggest that an active CaMKII is
required in both phases of ERK1/2 phos-
phorylation induced by CRH in HT22-
CRHR1 cells.
Because calcium/calmodulin stimu-
lation of CaMKII activity is important
for ERK1/2 activation, then chelation
Figure 9. Calcium and CaMKII are involved in both phases of CRH-induced ERK1/2 activation.
A, HT22-CRHR1 cells were loaded with Fluo-4 AM, as described in Materials and Methods, and a
time course of intracellular calcium in single HT22-CRHR1 cells in response to 100 nM CRH was
performed. Fluorescence was determined as described in Materials and Methods. Results are
presented as the peak change in fluorescence from resting levels SEM from 3 independent
experiments. B, HT22-CRHR1 cells were loaded with Fluo-4 AM, as described in Materials and
Methods, and cells were pretreated with EGTA (2 mM), U-73122 (5 M), or vehicle for control for
30 minutes. Fluorescence was determined as described in Materials and Methods. Results are
presented as the percentage of calcium response (peak change in fluorescence from resting levels)
obtained at control conditions SEM from 3 independent experiments. ** P .01 compared
with the control (vehicle plus CRH). Statistical analysis was performed using a one-way ANOVA
followed by post hoc Scheffé’s test. C–E, HT22-CRHR1 cells were pretreated for 30 minutes with
10 M KN-62 (C), 5 M BAPTA-AM (D), 2 mM EGTA (E), or 5 M U-73122 (E) for 30 minutes
and stimulated with 100 nM CRH for the indicated times. Controls were preincubated with
vehicle. pERK1/2, total ERK1/2, and pCaMKII were determined by Western blot. pERK1/2 and
ERK1/2 signals were quantified by densitometry as described in Materials and Methods, and each
value of pERK1/2 was normalized to total ERK1/2. Results are expressed as the percentage of
maximum pERK1/2 obtained at 3 minutes of stimulation in the absence of inhibitor SEM from 3
independent experiments. Bottom panels show Western blots of pERK1/2 (top), total ERK1/2
(middle), and pCaMKII (bottom) from a representative experiment. * P .05; ** P .01
compared with vehicle plus CRH treatment at the same time point. Statistical analysis was
performed using a one-way ANOVA followed by post hoc Scheffé’s test.
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of intracellular calcium should also affect pERK1/2 levels
induced by CRH. HT22-CRHR1 cells were pretreated
with cell-permeable calcium chelator BAPTA-AM (5 M),
and CRH-induced pERK1/2 was analyzed. Similar to the
effect observed with the CaMKII inhibitor KN-62, cal-
cium chelation affected ERK1/2 activation at early and
late time points of CRH stimulation (Figure 9D). Accord-
ingly, pCaMKII levels were also reduced in HT22-
CRHR1 cells pretreated with BAPTA-AM before CRH
stimulation (Figure 9D).
Therefore, we explored the main source of calcium
involved in CRH-induced ERK1/2 activation. pERK1/2
levels were analyzed after 100 nMCRHstimulation in the
absence or presence of 2 mM EGTA (no extracellular
calcium), or 5 MU-73122 (no PLC-dependent intracel-
lular calcium mobilization). As shown in Figure 9D,
HT22-CRHR1 cells depleted of total calcium (BAPTA-
AM) showed reduced ERK1/2 activation compared with
control cells. Similar results were observed when cells
were depleted of extracellular calcium with EGTA (Fig-
ure 9E). Notably, CRH-induced pERK levels were sim-
ilar compared with control cells, unlike glutamate-in-
duced ERK1/2 activation that was significantly
reduced when cells were preincubated with U-73122
(Supplemental Figure 4), demonstrating that CRH ac-
tivation of this MAPK is independent of PLC activity
(Figure 9E). In this line, the calcium chelator
BAPTA-AM also affected ERK1/2 activation induced
by CRH at lower concentrations (1 nM), revealing that
calcium still plays a role in CRH signaling at subopti-
mal concentrations for Gq coupling to CRHR1 (68) in
HT22-CRHR1 cells (Supplemental Figure 5).
Taken together, these results demonstrate that CRH
elevates intracellular calcium levels imported from an ex-
tracellular source and that calcium-mediated activation
of CaMKII is necessary to activate ERK1/2 by CRH in
HT22-CRHR1 cells.
Discussion
In this work, we describe the molecular components and
cellular mechanisms involved in ERK1/2 activation by
CRH in neuronal hippocampalHT22 cells.We document
for the first time that ERK1/2 activation in response to
CRH is biphasic in these cells (Figure 1A). This is a novel
CRH-induced ERK1/2 phosphorylation pattern because
a number of studies in non-neuronal cellular models did
not show different waves of ERK1/2 activation (24–26,
29), and it may reflect a specific CRH response in a neu-
ronal context. Our group and others have used AtT-20
cells to study molecular aspects of CRH signaling in the
pituitary, where cAMP is involved in ERK1/2 activation
induced by CRH. Moreover, our previous work demon-
strated that ERK1/2 activation in corticotrophs is impli-
cated in the expression of POMC (24). However, a study
of CRH signaling in neurons of specific brain areas like
the hippocampus had not been performed to date. Our
results showing the involvement of at least 2 distinct ac-
tivation mechanisms (one cAMP-dependent and other
CRHR1 internalization-dependent) for CRH-induced
ERK1/2 activation are not found in AtT-20 cells (24, 25)
and may be specific to the cellular environment. Biphasic
ERK1/2 activation involving different signaling pathways
has been previously demonstrated for other 7 transmem-
brane domain receptors, although the biological basis of
the differential cellular responses and its physiological
consequences are far frombeing understood (69, 70).Our
data indicate that the mechanisms and molecular compo-
nents underlying the first early and second late activation
of ERK1/2 are distinct. The mechanisms and molecular
players reported in this work are summarized in the
model depicted in Figure 10.
pERK1/2 in CRH-stimulated HT22-CRHR1 cells was
primarily detected at the cell surface and in the cytoplasm,
with very low amounts translocated to the nucleus (Fig-
ures 2 and 3). Although ERK1/2 are common effectors of
multiple signaling pathways, this pattern of activated
ERK1/2 subcellular distribution was CRH-specific in
these hippocampal neuronal cells and clearly different
from that obtained using PDGF as stimulus. In HT22-
CRHR1 cells, the pERK1/2 localization pattern triggered
by CRH is consistent with a contribution of 2 pathways:
a G protein-mediated pERK1/2 that is distributed in vari-
able amounts in the cytoplasm and nucleus and a long-
lasting -arrestin–mediated pERK1/2 that is localized in
membrane and cytoplasmic vesicles (71). Interestingly,
immunocytochemistry and confocal analysis detected ex-
tranuclear pERK1/2 in all the specific mouse brain areas
in which intracerebroventricular administered CRH acti-
vates the MAPKs (12).
In our system, internalization of the CRHR1 appears
to be rapid (Figure 2) as previously observed in trans-
fected HEK293 and primary cortical neurons (18, 52). In
vivo studies in rodents have documented a relationship
between CRHR1 internalization and stress in specific
brain areas. Transgenic mice in which CRH overexpres-
sion was restricted to limbic structures showed that acute
stress resulted in a significant reduction of CRHR1 ex-
pression in the amygdala (72), and evidence of CRHRs
stress-induced trafficking was reported in rat locus coer-
uleus and dorsal raphe (73, 74).
Different ERK1/2 activation mechanisms downstream
of CRHR1 have been described depending on the cellular
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model analyzed (12, 16–21, 23, 24). Classically, acti-
vated CRHRs bind the Gs protein and activate AC, lead-
ing to an increase in intracellular cAMP. In this work, we
demonstrated that AC is involved in CRH-induced
ERK1/2 activation in the early phase but seems dispens-
able for the late ERK1/2 activation. A crucial player link-
ing cAMP to ERK1/2 activation is the MAPKKK B-Raf.
Our results provide evidence for a critical role of this
MAPKKK in early ERK1/2 activation induced by CRH in
HT22-CRHR1 cells. Notably, B-Raf provides specificity
to CRH signaling because B-Raf silencing experiments
(Figure 4, C and D) showed that this MAPKKK is not
required for PDGF-activated ERK1/2, demonstrating
that 2 different stimuli (CRH vs PDGF), leading to the
activation of same effectors (pERK1/2), signal through
different molecular components in the same cells.
Surprisingly, late ERK1/2 activation was not affected
by B-Raf silencing. Activation of the ERK1/2 signaling
cascade by CRHR1 is a complex process that may involve
multiple mechanisms and molecular components. Sus-
tained MAPK activation mediated by -arrestin requires
the assembly of a MAPKKK-MAPKK-
MAPK--arrestin signaling complex
(75, 76). In recent years, the fact that
Raf proteins operate as homodimers
and heterodimers became evident (77,
78). Although B-Raf is the most active
MAPKKK, it may not be the only
MAPKKK involved in CRH/CRHR1-
activated ERK1/2. That scenario may
explain the apparent independence of
B-Raf of the late phase of CRH-in-
duced pERK1/2 (Figure 4C) as well as
the incomplete blockage of ERK1/2 ac-
tivation in cells transfected with B-Raf
siRNA. Moreover, the particular situ-
ation generated by silencing B-Raf may
lead to a compensation response of the
MAPKKK activity by other Raf family
members. Indeed, it has been reported
that conditional ablation of B-Raf in
neuronal precursors in mice leads to
increased Raf-1 recruited to MEK1 in
oligodendrocytes (79). Furthermore, a
recent study using single B-Raf and
Raf-1 knockouts in mice showed that
these 2 Raf proteins can compensate
for each other in certain Raf signaling
processes (80).
In our previous work, we character-
ized the B-Raf interactome in this hip-
pocampal neuronal cell line under
basal conditions, usingMS-based proteomic analysis, as a
starting point to understand MAPK pathways in neurons
(49). Given the role of B-Raf in CRH signaling in HT22-
CRHR1 cells, we performed a similar analysis to identify
B-Raf–associated proteins in CRH-stimulated cells. To
avoid biochemical artifacts from overexpression studies,
B-Raf immunoprecipitations were performed under en-
dogenous B-Raf expression conditions. Table 1 shows a
list of selected B-Raf partners whose role in ERK1/2 stim-
ulation by CRH was analyzed in the present study. The
functional analysis performed on this subset of identified
B-Raf partners suggests that other biomolecular interac-
tions detected would also play a role in CRH signaling
and will be the focus of future experiments.
B-Raf biological activity was found to be dependent on
14-3-3s binding (81). Our results indicate that 14-3-3
proteins are essential at B-Raf–dependent time points of
ERK1/2 activation by CRH. However, because 14-3-3s
play a central role in the activation process of all Raf
kinases (56), the late phase of CRH-induced pERK1/2 is
also expected to be regulated by 14-3-3 proteins. In line
Figure 10. Molecular mechanisms involved in biphasic ERK1/2 activation triggered by CRH-
activated CRHR1 in hippocampal neuronal cells. Early phase is depicted on the left. Upon
CRHR1 activation by CRH, the coupled Gs protein leads to AC stimulation with a consequent
increase of intracellular cAMP levels and PKA activation. In addition, CRH also triggers rapid
calcium influx and activation of CaMKII. Association of PKA-activated small G proteins Rap1
and Ras to B-Raf induces conformational changes and stimulation of this MAPKKK.
Phosphorylated (activated) B-Raf is represented in a complex with the interacting proteins
whose role in CRH signaling is described in this work. B-Raf serine/threonine kinase activity
triggers sequential phosphorylation and activation of MEK1/2 and ERK1/2 of the early phase.
Late phase is depicted on the right. Shortly after stimulus, activated dynamin (Dyn) and
vimentin, identified as B-Raf partners, become involved in clathrin-coated pits containing
CRHR1/-arrestin2 complexes. Binding of -arrestin2 to agonist-occupied CRHR1 triggers
receptor internalization and the assembly of a MAPK activation complex resulting in ERK1/2
activation of the late phase. Activated CaMKII is also involved in this sustained phase,
suggesting its potential role in CRHR1-internalization–dependent signaling. Activated
(phosphorylated) ERK1/2 (pERK1/2) generated from both mechanisms is mainly retained in the
cytoplasm with very low amounts translocated to the nucleus. Cellular mechanisms and
physiological consequences of the distribution of CRH-activated ERK1/2 remain still unknown.
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with this hypothesis, when HT22-CRHR1 cells were
transfected with DN–14-3-3, both phases of ERK1/2 ac-
tivation were affected (Supplemental Figure 6).
The catalytic subunit of PKA was identified as a B-Raf
partner in HT22-CRHR1 cells treated with CRH (Table
1). Previous work in corticotrophs demonstrated that a
rapid CRH/CRHR1-triggered ERK1/2 activation takes
place downstream of the PKA (24). Our results suggest
that, in neuronal cells, a similar pathway operates in the
early-detected ERK1/2 activation triggered by CRH.
However, although many of the cellular effects induced
by cAMP require PKA activation, ERK1/2 phosphoryla-
tion could also proceed via alternative mechanisms (82).
In a recent work, it was demonstrated that exchange pro-
tein activated by cAMP can also mediate CRH-induced
ERK1/2 signaling in AtT-20 corticotrophs (25). That pos-
sibility may explain incomplete blockage of ERK1/2 ac-
tivation in the early phase of H89-pretreated cells. Future
investigations analyzing the role of exchange proteins ac-
tivated by cAMP in ERK1/2 activation by CRH in hip-
pocampal cells should be performed.
We found that 2 members of the Ras family of small G
proteins, Rap1 and Ras, play a role in CRH-induced
ERK1/2 activation at early time points. These results are
consistent with the fact that B-Raf, unlike Raf-1, can be
activated by these 2 related small G proteins via PKA-
dependent mechanisms (83). CRH stimulation of the
MAPKpathway involvingRap1was previously described
in corticotrophs (24). In the mouse hippocampus, both
Rap1 and Ras link increments in intracellular cAMP to
ERK1/2 activation, and interestingly, Rap1 is required to
activate a specific membrane-associated pERK1/2 pool
implicated in regulation of learning andmemory (83, 84).
It is noteworthy that short times of CRH stimulation
also identified molecular associations whose role was ev-
ident in the late phase without showing a remarkable
contribution to the first phase of ERK1/2 activation, in
which B-Raf is a key player. Besides its role as a
MAPKKK, proteins of the Raf family behave as scaffolds
interactingwith a complex network of numerous proteins
that are also engaged in dynamic multimolecular com-
plexes. Some molecular components may be detected
with B-Raf at a time that may not reflect its precise stage
of action. Molecular interactions established at some
point in the cell at a basal and/or stimulated situationmay
operate independently of each other in a specific signaling
phase. One may hypothesize that an interaction between
B-Raf and a given partner may be necessary for its func-
tion in a later stage. Thatmay explain the identification of
dynamin-1 and vimentin as B-Raf partners in our studies.
The intermediate filament protein vimentin is a target
of a number of kinases. Vimentin was reported to interact
with pERK1/2 and to protect these activated MAPKs
from dephosphorylation in vitro (85). In our work, vi-
mentin was detected in B-Raf immunoprecipitates at
basal and after CRH stimulation. The association of vi-
mentin and vimentin kinases with Raf-1 has been de-
scribed, and vimentin phosphorylation was found to be
dependent on activated Raf-1 (86). B-Raf may act simi-
larly to Raf-1 and regulate vimentin function by promot-
ing specific phosphorylations that are required for vimen-
tin activation. The -arrestin2–dependent (late) phase of
pERK1/2 triggered by CRHmay require activated vimen-
tin that was generated at early time points of CRH stim-
ulation. Interestingly, vimentin was found to potently
stimulate the dynaminGTPase activity (87) andwas iden-
tified, as well as dynamin-1, as a -arrestin2–interacting
partner (88).
Our results demonstrate that the late phase of CRH-
induced ERK1/2 activation depends on receptor internal-
ization. In addition to leading to an almost complete
blockage of the late phase, alteration of receptor internal-
ization also partially affected the early phase of CRH-
induced ERK1/2 activation. Because internalization of
the CRHR1 initiates shortly after stimulus in HT22-
CRHR1 cells, an overlap of ERK1/2 activation by both
mechanisms may contribute to the pERK1/2 signal de-
tected at the initial time points analyzed, although the G
protein-dependent pathway is the principal mechanism
that activates ERK1/2 at the early phase.
The internalization of many GPCRs occurs primarily
via clathrin-coated pits involving proteins of the arrestin
family with a crucial role, -arrestins 1 and 2 (89). No-
tably, in HEK293 cells and primary cortical neurons
transfected with CRHR1, the CRH-activated receptor
was found to interact selectively with -arrestin2 (52).
Indeed, we observed that when HT22-CRHR1 cells are
depleted of -arrestin2, the second phase of CRH-
induced ERK1/2 activation is affected. These findings
suggest that controlling the fate of internalized CRHR1
(recycling to the cell surface or lysosomal degradation)
might represent a new level of regulation of CRHR1 sig-
naling. The study of these new mechanisms of signaling
regulation as well as the temporal aspects of receptor
resensitization and turnover will provide important in-
sight in our understanding of CRHR1 signaling in neu-
rons and should be further explored in the future. Specif-
ically, unraveling the mechanism of how CRHR1
internalizes might result in unprecedented targets that can
be used to reduce pathologically relevant enhancement of
CRH/CRHR1 signaling.
CRH signaling through Ca2 has been documented in
many cellular systems. Previous reports have shown that
CRHR1 stimulates calcium mobilization in HEK-293
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cells but not in human neuroblastoma SK-N-MC cells,
demonstrating once again the relevance of the cellular
context (27, 28). In this line, we confirmed that CRHdoes
not stimulate calcium mobilization in the neuronal
HT22-CRHR1 cells, but instead, CRH stimulates the ion
influx from the extracellular environment, as previously
observed (24) for AtT-20 corticotrophs (Figure 9B).
The cross talk between calcium and ERK1/2 pathways
has been studied in detail (90, 91). Our results demon-
strate that calcium influx and CaMKII are essential to
activate the B-Raf–mediated (early) and the -arrestin–
mediated (late) phase of CRH-induced ERK1/2 activation
(Figure 9). CaMKII association with Raf kinases regulat-
ing their activity is already known (90). In our system,
CaMKII is a B-Raf partner and may be affecting early
pERK1/2 levels by regulating its MAPKKK activity.
However, a CaMKII role in the late phase of ERK1/2
activation may be different. CaMKII is known to bind to
-arrestins (88), and an essential role for -arrestin in
mediating CaMKII signaling after 1-adrenoreceptor
stimulation has been shown (92). Interestingly, in the
same line, the interaction of calmodulin, a critical factor
needed for CaMKII activation, with the 5-HT2C receptor
has been found to be necessary for -arrestin–dependent
ERK1/2 signaling (93). In our system, CaMKII may be
part of a complex with -arrestins that could translocate
to agonist-occupied CRHR1 on the plasma membrane
and trigger -arrestin2–dependent (late phase) ERK1/2
activation induced by CRH.
In conclusion, in this work, we describe for the first
time a comprehensive study on signaling mechanisms
and molecular components involved in CRH-induced
ERK1/2 activation in neuronal cells. Our results provide
novel evidence that CRH activates ERK1/2 through dif-
ferent pathways involving different intracellular mole-
cules that may become potential targets to develop ther-
apies for affective disorders such as depression and
anxiety. Given the importance of modulating CRHR1
responses in pathological situations, our approach con-
stitutes a basis to design therapies for disorders caused by
an impaired CRH/CRHR1 system.
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